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Abstract
Background: Polymorphisms in the potassium channel, voltage-gated, KQT-like subfamily, member 1 (KCNQ1) have recently
been reported to associate with type 2 diabetes. The primary aim of the present study was to investigate the putative
impact of these KCNQ1 polymorphisms (rs2283228, rs2237892, rs2237895, and rs2237897) on estimates of glucose
stimulated insulin release.
Methodology/Principal Findings: Genotypes were examined for associations with serum insulin levels following an oral
glucose tolerance test (OGTT) in a population-based sample of 6,039 middle-aged and treatment-naı ¨ve individuals. Insulin
release indices estimated from the OGTT and the interplay between insulin sensitivity and insulin release were investigated
using linear regression and Hotelling T2 analyses. Applying an additive genetic model the minor C-allele of rs2237895 was
associated with reduced serum insulin levels 30 min (mean6SD: (CC) 2776160 vs. (AC) 2806164 vs. (AA) 2996200 pmol/l,
p=0.008) after an oral glucose load, insulinogenic index (29.6617.4 vs. 30.2618.7vs. 32.2622.1, p=0.007), incremental area
under the insulin curve (20,477612,491 vs. 20,503612,386 vs. 21,810614,685, p=0.02) among the 4,568 individuals who
were glucose tolerant. Adjustment for the degree of insulin sensitivity had no effect on the measures of reduced insulin
release. The rs2237895 genotype had a similar impact in the total sample of treatment-naı ¨ve individuals. No association with
measures of insulin release were identified for the less common diabetes risk alleles of rs2237892, rs2237897, or rs2283228.
Conclusion: The minor C-allele of rs2237895 of KCNQ1, which has a prevalence of about 42% among Caucasians was
associated with reduced measures of insulin release following an oral glucose load suggesting that the increased risk of
type 2 diabetes, previously reported for this variant, likely is mediated through an impaired beta cell function.
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Introduction
Type 2 diabetes is a common complex disorder, characterised
by chronic hyperglycemia as the result of an incapacity of the
pancreatic beta cells to compensate for the degree of insulin
resistance [1]. Glucose-stimulated insulin secretion is biphasic;
impaired or absent first-phase insulin secretion is an early feature
of type 2 diabetes, while second-phase insulin secretion deterio-
rates during progression of the disease. Biphasic insulin secretion is
triggered by electrical signalling in the beta cell as a result of a
functional interplay between KATP channels, KV-channels and
voltage-dependent Ca
2+ channels [2–7]. Hence, genes involved in
maintaining and regulating the electrogradient in the beta cells are
plausible candidate genes for type 2 diabetes. To date, genetic
variation in voltage-dependent Ca
2+ channels (CACNA1E) and
KATP (KCNJ11) channels have been shown to influence insulin
secretion and type 2 diabetes risk [8,9], and genome-wide
association studies (GWAS) for type 2 diabetes in Caucasians
have proven the importance of genes coding for proteins involved
in insulin secretion [10–14]. Two independent GWAS in Japanese
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potassium channel, voltage-gated, KQT-like subfamily, member 1
(KCNQ1), and for the two studies, the association was replicated in
Danish and Singaporean individuals (meta-analysis: rs2237895
OR=1.23 (1.18–1.29), p,1.0610
216 and rs2237897 OR=1.33
(1.24–1.41), p,1.0610
216) [15], and in Chinese, Korean and
Swedish individuals (meta-analysis: rs2237895 OR=1.31 (1.25–
138), p=6.1610
226, and rs2237892 OR=1.40 (1.34–1.47),
p,1.7610
242 [16].
KCNQ1 is located on chromosome 11p15.5, a region that also
contains other genes which have previously been associated with
type 2 diabetes, e.g., CDKN1C [17]. Linkage to type 2 diabetes has
similarly been identified at chromosome 11p12–p13 in a Japanese
study [18]. Mutations in KCNQ1 are known to cause the
autosomal-recessive and -dominant forms of the long QT-
syndrome (Jervell and Lange-Nielsen [19] and Romano-Ward
[20]), and common variation has also been genome-wide
associated with altered QT interval [21,22]. KCNQ1 encodes the
pore-forming a-subunit of the IKs-channel (KV7.1) which is
expressed in the human heart and pancreas as well as in the
kidney, placenta, liver, lung, and intestine [15,23]. The basal pore
of the KV7.1-channel consists of four KCNQ1 subunits, which
assemble with different KCNE b-subunit family members (e.g.,
KCNE1 in cardiac tissue and KCNE3 in colonic tissue) to form
protein complexes with different potassium current properties
[24]. From studies in INS-1 cells it has been suggested that
KCNQ1 assembles with KCNE2 in insulin-secreting cells, and
that blocking of the KCNQ1 K
+ channel with the sulphonamide
analogue 293B reduces whole beta cell outward currents with
60%, and that the insulin secretion significantly increases in the
presence of both 293B and tolbutamide [25].
To test the hypothesis that the recently reported type 2 diabetes-
associated variants in KCNQ1 have an effect on insulin release, we
investigated rs2283228, rs2237892, rs2237895, and rs2237897 for
association with serum insulin levels during an oral glucose
tolerance test (OGTT) in a population-based sample of 6,039
middle-aged and treatment-naı ¨ve Danes.
Results
Effect of the common KCNQ1 rs2237895 on measures of
serum insulin release
Four KCNQ1 polymorphisms (rs2237892, rs2283228,
rs2237895, and rs2237897) previously shown to associate with
type 2 diabetes [15,16] were genotyped in 6,164 Danes (Table S1),
who were part of the Danish case-control sample in the study by
Unoki et al. [15]. These variants were investigated for an
association with type 2 diabetes-related quantitative traits in the
population-based Inter99 study sample involving 6,039 treatment-
naı ¨ve middle-aged individuals of whom 4,568 were normal glucose
tolerant according to WHO criteria. Three of the variants
(rs2237892, rs2283228, and rs2237897) were not associated with
type 2 diabetes related quantitative traits (Tables S2–S7).
However, both glucose tolerant individuals and treatment-naı ¨ve
study participants of Inter99 with the minor C-allele of KCNQ1
rs2237895 (minor allele frequency=42.5%) had significantly
lower measures of serum insulin and serum C-peptide release
under an additive genetic model (Table 1, 2). No differences in
insulin resistance (HOMA-IR) were observed (Table 1, 2). Data on
D9 and r
2 for the four SNPs are given in (Table S8).
In order to further investigate a putative beta cell abnormality,
the interplay between insulin release (Insulinogenic index: I/G30),
insulin resistance (Homeostasis model assessment of insulin
resistance: HOMA-IR) and the genetic predisposition to type 2
diabetes with KCNQ1 rs2237895, we applied the multivariate
Hotelling’s T
2 method to simultaneously test the effect of genotype
on I/G30 and HOMA-IR in the sample of glucose tolerant
individuals. Significant multivariate association with the
rs2237895 C-risk-allele and the combination of I/G30 and
HOMA-IR was demonstrated (p=0.004; pdominant=0.004)
(Figure 1).
Discussion
Current knowledge of the KCNQ1 protein in INS-1-cells and
the association of the KCNQ1 polymorphisms with type 2 diabetes
in two large Japanese studies [15,16] led us to investigate a role for
these variants in type 2 diabetes-related quantitative traits
(especially serum insulin release) in the population-based Inter99
study sample. Individuals with the minor C-allele of KCNQ1
rs2237895 had significantly reduced estimates of first-phase insulin
release as measured by serum insulin concentration at 30 min and
I/G30 and the association was not dependent on the level of
insulin sensitivity suggesting a true beta cell abnormality (Figure 1).
The KV-channels are believed to play an important role in the
pancreatic beta cells mediating repolarisation of the membrane
terminating Ca
2+-influx and insulin secretion, and a KV-channel
knock-out in rat islets as well as pharmacological inhibition of KV-
channels in mouse beta cells have been reported to enhance
glucose-stimulated insulin secretion [4–7]. The KV7.1 channel,
encoded by KCNQ1, is expressed in INS-1 cells and has been
suggested to play an important role in maintaining the membrane
potential in these cells [25]. Based on in vitro data and the
association with type 2 diabetes, there is compelling evidence
suggesting an effect also on type 2 diabetes-related quantitative
traits with variation in this gene. In context of the known function
of the protein encoded by KCNQ1 it is also interesting to note the
potential relationship between an increased risk of sudden cardiac
death with unknown etiology in individuals with diabetes [26],
supported by recent studies showing genome-wide significant
association with common variation in KCNQ1 and QT-interval of
the ECG [21,22], as well as association with the Mendelian long
QT syndrome and sudden death [27].
Furthermore, an in silico protein-protein interaction network
analyses, performed as in [28], suggested several interesting
protein interactions and pathways that could potentially affect
insulin secretion, e.g., AKAP9, encoding the Yotiao-protein
(Figure 2). This protein has previously been reported to form a
large macromolecular complex with KCNQ1 important in
coordinating cAMP-dependent PKA phosphorylation of the
KCNQ1-channel [29]. A mutation in AKAP9 has also been shown
to cause long QT syndrome subtype 11 by disrupting the binding
to KCNQ1 leading to reduced cAMP-stimulated PKA phosphor-
ylation of the KCNQ1-channel and a prolonged repolarization
period [30]. In addition, anchoring of PKA to AKAPs is involved
in GLP-1-mediated but not glucose-mediated insulin secretion
[31].
In recent studies [15,16] large differences in allele frequencies
were observed for KCNQ1 rs2237892, rs2283228, and rs2237897
between Japanese and Scandinavian individuals. Given the low
allele frequency for these three variants in our Caucasian
population the statistical power to identify an association with
type 2 diabetes related quantitative traits with an equal effect size
as in the Japanese studies was low. This fact might explain the lack
of association with measures of serum insulin release for these
variants. However, it could also indicate that these variants are not
causative but rather good proxies for the causative variant/s in the
Japanese population and poorer proxies in individuals of
KCNQ1, Reduced Insulin Release
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rs2237895 is in strong LD with a causative variant/s in this or
in another nearby gene in this heavily imprinted and gene-dense
region since the selection of these variants were based on previous
findings linking them to an increased risk of type 2 diabetes. In this
context it is important to notice that polymorphisms in the
neighbouring CDKN1C have been associated with increased birth
weight [17], and that variation in the CDKN family (CDKN2A/B
locus; chromosome 9p21) has been associated with type 2 diabetes
in recent GWAS- and GWAS-replication studies [10–12,14,32].
Thus, given the large allele-frequency differences of KCNQ1
variants observed in previous studies [15,16], genotyping and re-
sequencing of the KCNQ1 locus and nearby loci on chromosome
11p in additional populations may help identifying the causative
variant/s explaining the regional association with reduced insulin
release and type 2 diabetes. Using the overly conservative
Bonferroni correction the present data would not hold for multiple
testing, but since the measures of insulin release during the OGTT
are highly correlated we believe such corrections are too
conservative. Although Tan et al. [33] have also reported
association of variation in the KCNQ1 locus and impaired beta-
cell function in 3734 Asians additional replication attempts in large
independent studies with careful measurements of stimulated
insulin release are warranted.
In conclusion, we report insulin sensitivity independent impair-
ment of insulin release following an oral glucose load in a large
population of middle-aged treatment naı ¨ve individuals carrying the
type 2 diabetes associated minor C-allele of KCNQ1 rs2237895.
Materials and Methods
Subjects
The four polymorphisms (rs2283228, rs2237892, rs2237895,
rs2237897) were genotyped in 6,164 Danes from the population-
based Inter99 study sample [34] (Table S1). The glucose tolerance
status of these participants were characterised according to WHO
criteria [1]; normal glucose tolerance (n=4,568), impaired fasting
glycaemia (n=508), impaired glucose tolerance (n=707), or
screen-detected T2D (n=256); 125 had known treated type 2
diabetes and were excluded from the quantitative trait analyses.
The glucose tolerant individuals from the Inter99 study sample
were part of the Danish control group in the previously published
Japanese KCNQ1 case-control study [15].
Ethics statement
All participants were of Danish nationality and informed written
consent was obtained from all participants before participation.
The studies were approved by the Ethical Committee of
Table 1. Anthropometrics and quantitative metabolic traits in 4,239 successfully genotyped individuals with normal glucose
tolerance from the population-based Inter99 study sample in relation to the rs2237895 genotypes of KCNQ1.
rs2237895
AA AC CC Padditive
N (m/w) 1,489 (689/800) 2,073 (972/1101) 677 (308/369)
Age (years) 45684 5 684 6 68
BMI (kg/m
2) 25.664.0 25.564.1 25.564.2 0.45
HOMA-IR 9.065.8 8.965.7 8.765.3 0.25
Glucose traits
Fasting p-glucose (mmol/l) 5.360.4 5.360.4 5.360.4 0.31
p-glucose at 30 min (mmol/l) 8.261.6 8.261.5 8.261.5 0.78
p-glucose at 120 min (mmol/l) 5.561.1 5.561.1 5.561.1 0.79
incAUC glucose 1816103 180699 1856101 0.62
Insulin traits
Fasting s-insulin (pmol/l) 38624 37624 37622 0.31
s-insulin at 30 min (pmol/l) 2996200 2806164 2776160 0.0076
s-insulin at 120 min (pmol/l) 1726136 1656126 1666135 0.38
incAUC insulin 21,810614,685 20,503612,386 20,477612,491 0.015
Fasting s-C-peptide (pmol/l) 5376201 5406224 5356208 0.89
C-peptide at 30 min (pmol/l) 2,0146704 1,9576681 1,9506702 0.022
C-peptide at 120 min (pmol/l) 2,0646788 2,0516795 2,0486811 0.42
incAUC C-peptide (pmol/l) 157,265653,026 153,022651,967 152,965653,118 0.045
Insulinogenic index 32622 30619 30617 0.0065
Disposition index 4.363.1 4.162.9 4.162.7 0.069
BIGTT-SI 10641 0 641 1 64 0.051
BIGTT-AIR 1,95061,179 1,8756964 1,8466951 0.04
The table includes unadjusted mean6S.D data. P-values shown are for an additive genetic model and are adjusted for age, BMI and sex. incAUC, incremental area under
the curve; HOMA-IR, homeostasis model assessment of insulin resistance; BIGTT-SI, BIGTT-insulin sensitivity; BIGTT-AIR, BIGTT acute insulin response.
doi:10.1371/journal.pone.0005872.t001
KCNQ1, Reduced Insulin Release
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Helsinki Declaration II.
Biochemical and anthropometric measurements
Height and body weight were measured in light indoor clothes
and without shoes, and BMI was calculated as weight (kg)
divided by height squared (m
2). Waist circumference was
measured in the standing position midway between the iliac
crest and the lower costal margin and hip circumference at its
maximum. In the Inter99 participants blood samples were drawn
after a 12-h overnight fast. Plasma glucose was analysed by a
glucose oxidase method (Granutest, Merck, Darmstadt, Ger-
many), HbA1C was measured by ion-exchange high-performance
liquid chromatography (normal reference range: 0.041–0.064)
and serum insulin (excluding des(31, 32) and intact proinsulin)
was measured using the AutoDELFIA insulin kit (Perkin-Elmer/
Wallac, Turku, Finland). Serum C-peptide concentrations were
measured by a time-resolved fluoroimmunoassay (AutoDELFIA
C-peptide kit; Perkin-Elmer/Wallac, Turku, Finland). BIGTT-
insulin sensitivity index (BIGTT-SI) and BIGTT-acute insulin
response (BIGTT-AIR) use information on sex and BMI
combined with analysis of plasma glucose and serum insulin
levels at time points 0, 30, and 120 min during an OGTT to
provide indices for SI and AIR that highly correlate with these
indices obtained during an intra-venous glucose tolerance test.
These indices were calculated as described elsewhere [35].
Insulinogenic index (I/G30) is an index of first phase insulin
release during an oral glucose challenge and was calculated as
fasting serum insulin subtracted from serum insulin at 30 min
[pmol/l] divided by plasma glucose at 30 min [mmol/l]. Insulin
resistance was determined by the Homeostasis model assessment
of insulin resistance (HOMA-IR) and calculated as fasting
plasma glucose [mmol/l] multiplied by fasting serum insulin
[pmol/l] and divided by 22.5. The disposition index is an index
of insulin release in response to insulin resistance and was
calculated as I/G30 divided by HOMA-IR. The area under
curve for plasma glucose, serum insulin and serum C-peptide
were calculated using the trapezoidal method.
Bioinformatics-driven protein-protein interaction
analyses
In an attempt to detect proteins that interact with KCNQ1 we
applied protein-protein interaction analyses, performed as detailed
in [28].
Table 2. Anthropometrics and quantitative metabolic traits of a total of 5,597 successfully genotyped middle-aged and treatment-
naı ¨ve individuals from the Inter99 sample including the 4,239 glucose-tolerant individuals presented in Table 1.
rs2237895
AA AC CC Padditive
N (m/w) 1,933 (940/993) 2,721 (1,373/1,348) 943 (480/463)
Age (years) 46684 6 684 7 68
BMI (kg/m
2) 26.264.5 26.264.5 26.464.8 0.66
HOMA-IR 10.567.6 10.568.1 10.968.5 0.75
Glucose traits
Fasting p-glucose (mmol/l) 5.560.8 5.560.7 5.660.9 0.068
p-glucose at 30 min (mmol/l) 8.761.9 8.761.8 8.962.0 0.30
p-glucose at 120 min (mmol/l) 6.162.0 6.262.1 6.362.2 0.18
incAUCglucose 2196134 2206135 2286136 0.46
Insulin traits
Fasting s-insulin (pmol/l) 42627 42628 42628 0.50
s-insulin at 30 min (pmol/l) 3026198 2866179 2846169 0.0011
s-insulin at 120 min (pmol/l) 2196217 2156208 2186217 0.68
incAUC insulin 23,743616,727 22,500615,554 22,604615,572 0.0061
Fasting s-C-peptide (pmol/l) 5886255 5976283 6076286 0.46
C-peptide at 30 min (pmol/l) 2,0326713 1,9846722 1,9836716 0.013
C-peptide at 120 min (pmol/l) 2,30461,003 2,30761,030 2,32061,012 0.84
incAUC C-peptide 163,740657,671 160,006657,933 159,661658,165 0.035
Insulinogenic index 30.7621.3 28.8619.0 28.1617.5 0.00073
Disposition index 3.863.0 3.662.8 3.562.6 0.0097
BIGTT-SI 9.264.0 9.364.1 9.164.2 0.55
BIGTT-AIR 1,89261,140 1,84161,062 1,7846948 0.0083
Study participants are stratified according to rs2237895 genotypes of KCNQ1.
P-values shown are for an additive genetic model and are adjusted for age, BMI and sex. incAUC, incremental area under the curve; HOMA-IR, homeostasis model
assessment of insulin resistance; BIGTT-SI, BIGTT-insulin sensitivity; BIGTT-AIR, BIGTT acute insulin response.
doi:10.1371/journal.pone.0005872.t002
KCNQ1, Reduced Insulin Release
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Genotyping was performed using Taqman allelic discrimination
(KBiosciences, Herts, UK) with a success rate .96%. Discordance
was ,0.4% as judged from re-genotyping of 966 random
duplicate samples. Allele frequencies were in accordance with
HapMap (CEU) data (rs2237895 has not been genotyped in the
CEU population) and obeyed Hardy-Weinberg equilibrium
(p.0.4).
Statistical analyses
A general linear model was used to test for an association with
quantitative variables in the groups of normal glucose tolerant and
treatment-naı ¨ve individuals with abnormal glucose regulation
(impaired fasting glucose, impaired glucose tolerance and screen-
detected type 2 diabetes). Non-normally distributed data (measures
of serum insulin release and C-peptides, HOMA-IR, insulinogenic
index, disposition index and BIGTT) were logarithmically
transformed before analyses. All analyses were adjusted for age,
BMI, and sex.
The multivariate method, Hotelling T
2 [36], was applied to test
the simultaneous effect of genotype on serum insulin release (I/
G30) and insulin sensitivity (HOMA-IR) in the Inter99 sample of
non-diabetic individuals.
The statistical power to detect a difference in serum insulin at
30 min was estimated using simulations. We assumed an additive
genetic model for both the simulation of the data and for the
testing of the data using a linear model. We used the empirical
variance of the observed traits to simulate phenotypes from a
normal distribution so that the variance across genotypes is drawn
from the estimated variance. The power was estimated using 5,000
simulations and with a significance threshold of a=0.05. Based on
the different allele frequencies and the 4,568 normal glucose-
tolerant individuals, we estimated the effect sizes per allele of
quantitative traits for which we had 80 and 90% statistical power,
respectively, to detect an association. Depending on allele
frequency (4.0–42.5%) and assuming an additive model, we had
80% statistical power to detect an allele-dependent difference of
7.4–2.9% for serum insulin 30 min and 8.1–3.2% for I/G30.
Similarly, we had 90% statistical power to detect an 8.4–3.4% and
9.4–3.7% change per allele in serum insulin 30 min and I/G30,
respectively.
The statistical analyses were performed using R version 2.7.2
(available at http://www.r-project.org), SPSS (version 14.0,
Chicago, IL, USA) and PLINK [37]. P-values were not adjusted
for multiple hypothesis testing and a p-value of ,0.05 was
considered statistically significant.
Supporting Information
Table S1 Clinical characteristics of study participants. Data are
means6standard deviation. NGT, normal glucose tolerance, IFG,
impaired fasting glucose, IGT, impaired glucose tolerance, T2D,
type 2 diabetes.
Found at: doi:10.1371/journal.pone.0005872.s001 (0.02 MB
DOC)
Table S2 Anthropometrics and quantitative metabolic traits
among normal-glucose tolerant participants in the population-
based Inter99 study sample in relation to the rs2237897 genotypes
of KCNQ1. The table includes unadjusted mean6S.D data for a
total of 4,375 middle-aged individuals with normal glucose
tolerance stratified according to genotype. P-values shown are
for an additive genetic model and are adjusted for age, BMI and
Figure 1. Multivariate analysis on the effect of the minor C-allele of KCNQ1 rs2237895 on insulin release in response to the level of
insulin sensitivity in 4,568 glucose tolerant individuals from Inter99. The multivariate method, Hotelling’s T
2 [36], was applied to test the
simultaneous effect of genotype on insulinogenic index and HOMA-IR for rs2237895. Two-dimensional standard error of the means of each genotype
level for insulinogenic index and HOMA-IR were calculated for KCNQ1 rs2237895. Significant multivariate association with the minor C-allele of
rs2237895 was detected under an additive genetic model (p=0.004) suggesting that the association with insulin release was not dependent on the
level of insulin sensitivity but a true beta cell abnormality.
doi:10.1371/journal.pone.0005872.g001
KCNQ1, Reduced Insulin Release
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homeostasis model assessment of insulin resistance; BIGTT-SI,
BIGTT-insulin sensitivity; BIGTT-AIR, BIGTT acute insulin
response.
Found at: doi:10.1371/journal.pone.0005872.s002 (0.03 MB
DOC)
Table S3 Anthropometrics and quantitative metabolic traits
among normal-glucose tolerant participants in the population-
based Inter99 study sample in relation to the rs2283228 genotypes
of KCNQ1. The table includes unadjusted mean6S.D data for a
total of 4,381 middle-aged individuals with normal glucose
tolerance stratified according to genotype. P-values shown are for
an additive genetic model and are adjusted for age, BMI and sex.
incAUC, incremental area under the curve; HOMA-IR, homeo-
stasis model assessment of insulin resistance; BIGTT-SI, BIGTT-
insulin sensitivity; BIGTT-AIR, BIGTT acute insulin response.
Found at: doi:10.1371/journal.pone.0005872.s003 (0.03 MB
DOC)
Table S4 Anthropometrics and quantitative metabolic traits
among normal-glucose tolerant participants in the population-
based Inter99 study sample in relation to the rs2237892 genotypes
of KCNQ1. The table includes unadjusted mean6S.D data for a
total of 4,381 middle-aged individuals with normal glucose
tolerance stratified according to genotype. P-values shown are for
an additive genetic model and are adjusted for age, BMI and sex.
incAUC, incremental area under the curve; HOMA-IR, homeo-
stasis model assessment of insulin resistance; BIGTT-SI, BIGTT-
insulin sensitivity; BIGTT-AIR, BIGTT acute insulin response.
Found at: doi:10.1371/journal.pone.0005872.s004 (0.03 MB
DOC)
Table S5 Anthropometrics and quantitative metabolic traits in
the population-based Inter99 study sample in relation to the
rs2237897 genotypes of KCNQ1. Data are unadjusted mean6S.D
data for a total of 5,776 middle-aged individuals with either normal
glucose tolerance (n=4,375), impaired fasting glycemia (n=485),
impaired glucose tolerance (n=667) or screen-detected and
treatment-naı ¨ve type 2 diabetes (n=249) stratified according to
genotype. General linear regression analyses were used to calculate
differences between geneotypes and p-values shown are for an
additive genetic model and are adjusted for age, BMI and sex.
incAUC, incremental area under the curve; HOMA-IR, homeo-
stasis model assessment of insulin resistance; BIGTT-SI, BIGTT-
insulin sensitivity; BIGTT-AIR, BIGTT acute insulin response.
Found at: doi:10.1371/journal.pone.0005872.s005 (0.03 MB
DOC)
Table S6 Anthropometrics and quantitative metabolic traits in
the population-based Inter99 study sample in relation to the
rs2283228 genotypes of KCNQ1. Data are unadjusted mean6S.D
data for a total of 5,787middle-aged individuals with either normal
glucose tolerance (n=4,381), impaired fasting glycemia (n=491),
impaired glucose tolerance (n=667) or screen-detected and
treatment-naı ¨ve type 2 diabetes (n=248) stratified according to
genotype. General linear regression analyses were used to calculate
differences between geneotypes and p-values shown are for an
additive genetic model and are adjusted for age, BMI and sex.
incAUC, incremental area under the curve; HOMA-IR, homeo-
stasis model assessment of insulin resistance; BIGTT-SI, BIGTT-
insulin sensitivity; BIGTT-AIR, BIGTT acute insulin response.
Found at: doi:10.1371/journal.pone.0005872.s006 (0.03 MB
DOC)
Table S7 Anthropometrics and quantitative metabolic traits in
the population-based Inter99 study sample in relation to the
rs2237892 genotypes of KCNQ1. Data are unadjusted mean6S.D
data for a total of 5,781 middle-aged individuals with either normal
glucose tolerance (n=4,381), impaired fasting glycemia (n=483),
impaired glucose tolerance (n=672) or screen-detected and
treatment-naı ¨ve type 2 diabetes (n=245) stratified according to
genotype. General linear regression analyses were used to calculate
differences between geneotypes and p-values shown are for an
additive genetic model and are adjusted for age, BMI and sex.
incAUC, incremental area under the curve; HOMA-IR, homeo-
stasis model assessment of insulin resistance; BIGTT-SI, BIGTT-
insulin sensitivity; BIGTT-AIR, BIGTT acute insulin response.
Found at: doi:10.1371/journal.pone.0005872.s007 (0.03 MB
DOC)
Table S8 D9 and r2 measures for the investigated KCNQ1 SNPs.
Top triangle gives D9 and bottom triangle gives r2-values.
Found at: doi:10.1371/journal.pone.0005872.s008 (0.02 MB
DOC)
Figure 2. KCNQ1 -protein interaction analyses as estimated
from bioinformatics-driven protein-protein network analyses
including interactions transferred from other organisms by
orthology. PSMC x - Proteasome 26S subunit, ATPase, x; PSMD x –
Proteasome 26S subunit, ATPase, x; PSMB5 – Proteasome subunit, beta-
type, 5; AKAP9 – A-Kinase Anchor Protein 9; KCNE x – Potassium
Channel, Voltage-gated, ISK-related Subfamily, Member x.
doi:10.1371/journal.pone.0005872.g002
KCNQ1, Reduced Insulin Release
PLoS ONE | www.plosone.org 6 June 2009 | Volume 4 | Issue 6 | e5872Acknowledgments
The authors wish to thank Annemette Forman, Inge-Lise Wantzin, Tina
Lorentzen, and Marianne Stendal for technical assistance, Grete
Lademann for secretarial support, Arne Nielsen for data management
and Michel Kristensen for scientific management duties.
Author Contributions
Conceived and designed the experiments: JH GA TH OBP. Performed the
experiments: JH KB TSJ. Analyzed the data: JH KB. Contributed
reagents/materials/analysis tools: HU TSJ CP KBJ AS TL SB SM TH
OBP. Wrote the paper: JH GA TH OBP.
References
1. Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of
diabetes mellitus and its complications. Part 1: diagnosis and classification of
diabetes mellitus provisional report of a WHO consultation. Diabetic Medicine
15: 539–53.
2. Jacobson DA, Philipson LH (2007) Action potentials and insulin secretion: new
insights into the role of Kv channels. Diabetes Obesity and Metabolism 9:
89–98.
3. Kanno T, Rorsman P, Gopel SO (2002) Glucose-dependent regulation of
rhythmic action potential firing in pancreatic beta-cells by KATP-channel
modulation. J Physiol 545: 501–507.
4. MacDonald PE, Ha XF, Wang J, Smukler SR, Sun AM, et al. (2001) Members
of the Kv1 and Kv2 Voltage-Dependent K+ Channel Families Regulate Insulin
Secretion. Mol Endocrinol 15: 1423–1435.
5. MacDonald PE, Sewing S, Wang J, Joseph JW, Smukler SR, et al. (2002)
Inhibition of Kv2.1 Voltage-dependent K+ Channels in Pancreatic beta -Cells
Enhances Glucose-dependent Insulin Secretion. J Biol Chem 277: 44938–44945.
6. Roe MWm, Worley JF III, Mittal AA, Kuznetsov A, DasGupta S, et al. (1996)
Expression and Function of Pancreatic beta -Cell Delayed Rectifier K+
Channels. Role in Stimulus-Secretion Coupling. J Biol Chem 271:
32241–32246.
7. Zhang M, Houamed K, Kupershmidt S, Roden D, Satin LS (2005)
Pharmacological Properties and Functional Role of Kslow Current in Mouse
Pancreatic {beta}-Cells: SK Channels Contribute to Kslow Tail Current and
Modulate Insulin Secretion. J Gen Physiol 126: 353–363.
8. Gloyn AL, Weedon MN, Owen KR, Turner MJ, Knight BA, et al. (2003) Large-
scale association studies of variants in genes encoding the pancreatic beta-cell
KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the
KCNJ11 E23K variant is associated with type 2 diabetes. Diabetes 52: 568–72.
9. Holmkvist J, Tojjar D, Almgren P, Lyssenko V, Lindgren C, et al. (2007)
Polymorphisms in the gene encoding the voltage-dependent Ca2+ channel
CaV2.3 (CACNA1E) are associated with type 2 diabetes and impaired insulin
secretion. Diabetologia 50: 2467–2475.
10. Saxena R, Voight BF, Lyssenko V, Burtt NP, de Bakker PIW, et al. (2007)
Genome-wide association analysis identifies loci for Type 2 Diabetes and
triglyceride levels. Science 316: 1331–1336.
11. Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, et al. (2007) A genome-
wide association study of Type 2 Diabetes in Finns detects multiple susceptibility
variants. Science 316: 1341–1345.
12. Sladek R, Rocheleau G, Rung J, Dina C, Shen L, et al. (2007) A genome-wide
association study identifies novel risk loci for type 2 diabetes. Nature 445:
881–885.
13. Steinthorsdottir V, Thorleifsson G, Reynisdottir I, Benediktsson R, Jonsdottir T,
et al. (2007) A variant in CDKAL1 influences insulin response and risk of type 2
diabetes. Nat Genet 39: 770–775.
14. Zeggini E, Weedon MN, Lindgren CM, Frayling TM, Elliott KS, et al. (2007)
Replication of genome-wide association signals in UK samples reveals risk loci
for Type 2 Diabetes. Science 316: 1336–1341.
15. Unoki H, Takahashi A, Kawaguchi T, Hara K, Horikoshi M, et al. (2008) SNPs
in KCNQ1 are associated with susceptibility to type 2 diabetes in East Asian and
European populations. Nat Genet 40: 1098–1102.
16. Yasuda K, Miyake K, Horikawa Y, Hara K, Osawa H, et al. (2008) Variants in
KCNQ1 are associated with susceptibility to type 2 diabetes mellitus. Nat Genet
advanced online publication.
17. Nielsen E-M, Hansen L, Stissing T, Yanagisawa K, Borch-Johnsen K, et al.
(2005) Studies of variations of the cyclin-dependent kinase inhibitor 1C and the
cyclin-dependent kinase 4 genes in relation to type 2 diabetes mellitus and
related quantitative traits. Journal of Molecular Medicine 83: 353–361.
18. Mori Y, Otabe S, Dina C, Yasuda K, Populaire C, et al. (2002) Genome-Wide
Search for Type 2 Diabetes in Japanese Affected Sib-Pairs Confirms
Susceptibility Genes on 3q, 15q, and 20q and Identifies Two New Candidate
Loci on 7p and 11p. Diabetes 51: 1247–1255.
19. Neyroud N, Tesson F, Denjoy I, Leibovici M, Donger C, et al. (1997) A novel
mutation in the potassium channel gene KVLQT1 causes the Jervell and Lange-
Nielsen cardioauditory syndrome. Nature Genetics 15: 186–189.
20. Chouabe C, Neyroud N, Guicheney P, Lazdunski M, Romey G, et al. (1997)
Properties of KvLQT1 K+ channel mutations in Romano-Ward and Jervell and
Lange-Nielsen inherited cardiac arrhythmias. Embo J 16: 5472–9.
21. Newton-Cheh C, Eijgelsheim M, Rice KM, de Bakker PIW, Yin X, et al. (2009)
Common variants at ten loci influence QT interval duration in the QTGEN
Study. Nat Genet 41: 399–406.
22. Pfeufer A, Sanna S, Arking DE, Muller M, Gateva V, et al. (2009) Common
variants at ten loci modulate the QT interval duration in the QTSCD Study.
Nat Genet 41: 407–414.
23. Robbins J (2001) KCNQ potassium channels: physiology, pathophysiology, and
pharmacology. Pharmacol Ther 90: 1–19.
24. Grunnet M, Olesen SP, Klaerke DA, Jespersen T (2005) hKCNE4 inhibits the
hKCNQ1 potassium current without affecting the activation kinetics. Biochem
Biophys Res Commun 328: 1146–53.
25. Ullrich S, Su J, Ranta F, Wittekindt O, Ris F, et al. (2005) Effects of IKs channel
inhibitors in insulin-secreting INS-1 cells. Pflu ¨gers Archiv European Journal of
Physiology 451: 428–436.
26. Veglio M, Chinaglia A, Cavallo-Perin P (2004) QT interval, cardiovascular risk
factors and risk of death in diabetes. J Endocrinol Invest 27: 175–81.
27. Moss A, Schwartz P, Crampton R, Tzivoni D, Locati E, et al. (1991) The long
QT syndrome. Prospective longitudinal study of 328 families. Circulation 84:
1136–1144.
28. Lage K, Karlberg EO, Storling ZM, Olason PI, Pedersen AG, et al. (2007) A
human phenome-interactome network of protein complexes implicated in
genetic disorders. Nat Biotech 25: 309–316.
29. Marx SO, Kurokawa J, Reiken S, Motoike H, D’Armiento J, et al. (2002)
Requirement of a Macromolecular Signaling Complex for beta Adrenergic
Receptor Modulation of the KCNQ1-KCNE1 Potassium Channel. Science 295:
496–499.
30. Chen L, Marquardt ML, Tester DJ, Sampson KJ, Ackerman MJ, et al. (2007)
Mutation of an A-kinase-anchoring protein causes long-QT syndrome. Proc
Natl Acad Sci U S A 104: 20990–20995.
31. Lester LB, Langeberg LK, Scott JD (1997) Anchoring of protein kinase A
facilitates hormone-mediated insulin secretion. Proc Natl Acad Sci U S A 94:
14942–14947.
32. Grarup N, Rose CS, Andersson EA, Andersen G, Nielsen AL, et al. (2007)
Studies of association of variants near the HHEX, CDKN2A/B, and IGF2BP2
genes with Type 2 diabetes and impaired insulin release in 10,705 Danish
subjects: validation and extension of genome-wide association studies. Diabetes
56: 3105–3111.
33. Tan JT, Nurbaya S, Gardner D, Sandra Y, Tai ES, et al. (2009) Genetic
variation in KCNQ1 associates with fasting glucose and beta-cell function: A
study of 3734 subjects comprising three ethnicities living in Singapore. Diabetes
2009 Feb 27 [Epub ahead of print].
34. Jørgensen T, Borch-Johnsen K, Thomsen TF, Ibsen H, Glumer C, et al. (2003)
A randomized non-pharmacological intervention study for prevention of
ischaemic heart disease: baseline results Inter99. European Journal of
Cardiovascular Prevention & Rehabilitaion 10: 377–386.
35. Hansen T, Drivsholm T, Urhammer SA, Palacios RT, Va ¨lund A, et al. (2007)
The BIGTT Test: A novel test for simultaneous measurement of pancreatic
beta-cell function, insulin sensitivity, and glucose tolerance. Diabetes Care 30:
257–262.
36. Hotelling H (1931) The generalization of student’s ratio. Ann Math Statist 2:
360–378.
37. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, et al. (2007)
PLINK: A Tool Set for Whole-Genome Association and Population-Based
Linkage Analyses. American Journal of Human Genetics 81: 559–575.
KCNQ1, Reduced Insulin Release
PLoS ONE | www.plosone.org 7 June 2009 | Volume 4 | Issue 6 | e5872